文献速递泌尿生殖技术与安全PETMR

PSMA PET与mpMRI诊断前列腺癌淋巴结转移的系统综述与头对头比较Meta分析

PSMA PET vs. mpMRI for Lymph Node Metastasis of Prostate Cancer: A Systematic Review and Head-to-Head Comparative Meta-analysis.
PubMed 文献 · Acad Radiol · 2024-12-04

该系统综述与头对头比较Meta分析纳入23篇文献共3041例患者,比较PSMA PET与mpMRI诊断前列腺癌淋巴结转移的准确性。汇总分析显示PSMA PET敏感度为0.74(95%CI 0.62-0.85)、特异度为0.96(95%CI 0.93-0.98),mpMRI敏感度为0.45(95%CI 0.32-0.57)、特异度为0.92(95%CI 0.86-0.97);PSMA PET敏感度显著高于mpMRI(P<0.01),特异度无显著差异(P=0.18)。

要点

  • PSMA PET诊断前列腺癌淋巴结转移的汇总敏感度为0.74,mpMRI为0.45,前者显著更高(P<0.01)。
  • PSMA PET汇总特异度为0.96,mpMRI为0.92,两者特异度无显著差异(P=0.18)。
  • 初始分期亚组中PSMA PET敏感度显著高于mpMRI(P<0.01),特异度无显著差异(P=0.17)。

核心结论

  • PSMA PET检测前列腺癌淋巴结转移的敏感度高于mpMRI,尤其在初始分期中,但两者特异度无显著差异。
  • 由于异质性高,需要更多基于亚组的 study 来标准化影像实践并验证这些发现。

研究设计与样本

  • 系统综述与头对头比较Meta分析,检索PubMed、Embase和Web of Science截至2024年8月24日发表的文献。
  • 纳入比较PSMA PET与mpMRI检测前列腺癌淋巴结转移准确性的研究,共23篇文献、3041例患者。
  • 采用诊断准确性研究质量评价工具-2(Quality Assessment of Diagnostic Performance Studies-2)评价每项研究的质量。

诊断标准与关键数值

  • PSMA PET检测前列腺癌淋巴结转移的汇总敏感度为0.74(95%CI 0.62-0.85),汇总特异度为0.96(95%CI 0.93-0.98)。
  • mpMRI检测前列腺癌淋巴结转移的汇总敏感度为0.45(95%CI 0.32-0.57),汇总特异度为0.92(95%CI 0.86-0.97)。
  • PSMA PET敏感度显著高于mpMRI(P<0.01),两者特异度无显著差异(P=0.18)。
  • 初始分期中PSMA PET敏感度显著高于mpMRI(P<0.01),特异度无显著差异(P=0.17)。
  • 亚组分析显示[68Ga]Ga-PSMA-11 PET与[18F]F-PSMA-1007 PET敏感度均高于mpMRI(P=0.03、P<0.01),特异度无显著差异(P=0.10、P=0.73);[18F]F-DCFPyL PET敏感度(P=0.20)与特异度(P=0.43)均无显著差异。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文指出由于异质性高,需要更多基于亚组的研究来标准化影像实践并验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To compare prostate-specific membrane antigen (PSMA) PET with multiparametric MRI (mpMRI) in the diagnosis of lymph node metastasis (LNM) in prostate cancer.

METHODS: A comprehensive search of PubMed, Embase, and Web of Science identified studies published up to August 24, 2024. Studies comparing PSMA PET and mpMRI accuracy in detecting LNM in prostate cancer were included. The quality of each study was assessed using the Quality Assessment of Diagnostic Performance Studies-2 tool.

RESULTS: This study included 23 articles with a total of 3041 patients. The pooled analysis showed PSMA PET had a sensitivity of 0.74 (95% CI:0.62-0.85) and specificity of 0.96 (95% CI:0.93-0.98) for detecting prostate cancer LNM, while mpMRI had a sensitivity of 0.45 (95% CI:0.32-0.57) and specificity at 0.92 (95% CI:0.86-0.97). PSMA PET shows notably higher sensitivity than mpMRI, (P < 0.01) with no significant difference in specificity (P = 0.18). For initial staging, PSMA PET shows significantly higher sensitivity than mpMRI (P < 0.01), with no significant specificity difference (P = 0.17). Subgroup analysis showed that both [68Ga]Ga-PSMA-11 PET and [18F]F-PSMA-1007 PET had higher sensitivity than mpMRI (P = 0.03, P < 0.01) without significant differences in specificity (P = 0.10, P = 0.73). Meanwhile, there was no significant difference in the sensitivity (P = 0.20) and specificity (P = 0.43) of [18F]F-DCFPyL PET.

CONCLUSION: PSMA PET is more sensitive than mpMRI in detecting LNM in prostate cancer, especially for initial staging; however, there is no significant difference in specificity between the two. Due to the high heterogeneity, more subgroup-based studies are needed to standardize imaging practices and validate these findings.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Yang B, Dong H, Zhang S, et al. PSMA PET vs. mpMRI for Lymph Node Metastasis of Prostate Cancer: A Systematic Review and Head-to-Head Comparative Meta-analysis. Acad Radiol. 2024. PMID: 39632217. doi:10.1016/j.acra.2024.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。